OA10195A - Carbazole derivatives with 17 20-lyase-inhibiting activity - Google Patents

Carbazole derivatives with 17 20-lyase-inhibiting activity Download PDF

Info

Publication number
OA10195A
OA10195A OA60742A OA60742A OA10195A OA 10195 A OA10195 A OA 10195A OA 60742 A OA60742 A OA 60742A OA 60742 A OA60742 A OA 60742A OA 10195 A OA10195 A OA 10195A
Authority
OA
OAPI
Prior art keywords
compound
formula
group
daims
ylmethyl
Prior art date
Application number
OA60742A
Other languages
English (en)
Inventor
Peter Clive Cherry
John Derek Cocker
Andrew David Searle
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of OA10195A publication Critical patent/OA10195A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA60742A 1993-05-21 1995-11-17 Carbazole derivatives with 17 20-lyase-inhibiting activity OA10195A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310635A GB9310635D0 (en) 1993-05-21 1993-05-21 Chemical compounds

Publications (1)

Publication Number Publication Date
OA10195A true OA10195A (en) 1996-12-18

Family

ID=10736007

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60742A OA10195A (en) 1993-05-21 1995-11-17 Carbazole derivatives with 17 20-lyase-inhibiting activity

Country Status (19)

Country Link
EP (1) EP0699196A1 (enExample)
JP (1) JPH08510455A (enExample)
CN (1) CN1126473A (enExample)
AU (1) AU6928794A (enExample)
BG (1) BG100154A (enExample)
CA (1) CA2162921A1 (enExample)
CZ (1) CZ305195A3 (enExample)
FI (1) FI955587A7 (enExample)
GB (1) GB9310635D0 (enExample)
HU (1) HUT73790A (enExample)
IL (1) IL109703A0 (enExample)
NO (1) NO954681L (enExample)
OA (1) OA10195A (enExample)
PE (1) PE31195A1 (enExample)
PL (1) PL311702A1 (enExample)
SK (1) SK142495A3 (enExample)
TW (1) TW279866B (enExample)
WO (1) WO1994027989A1 (enExample)
ZA (1) ZA943494B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721943A4 (en) * 1993-09-30 1996-09-04 Yamanouchi Pharma Co Ltd AZOL DERIVATIVES AND PHARMACEUTICAL PREPARATIONS
WO1996014090A1 (en) * 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
NZ302392A (en) * 1995-03-01 1998-08-26 Yamanouchi Pharma Co Ltd Tricyclic substituted imidazole derivatives and medicaments thereof
CN1251577A (zh) * 1997-02-21 2000-04-26 武田药品工业株式会社 稠环化合物及其生产和应用
CA2429133C (en) 2000-11-17 2009-08-18 Takeda Chemical Industries, Ltd. Novel imidazole derivatives, production method thereof and use thereof
DE60144246D1 (de) 2000-11-20 2011-04-28 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
WO2002046186A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
AU2006262283B2 (en) * 2005-06-24 2011-10-13 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (SARM)
GB0525323D0 (en) 2005-12-13 2006-01-18 Sterix Ltd Compound
US8093279B2 (en) 2005-12-13 2012-01-10 Gillian Reed, legal representative Compound
CN100586932C (zh) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 抗肿瘤化合物及其制备方法
PE20121048A1 (es) 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
JP5964756B2 (ja) * 2010-02-04 2016-08-03 ラジウス ヘルス,インコーポレイテッド 選択的アンドロゲン受容体モジュレーター
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
KR101594660B1 (ko) 2010-08-04 2016-02-16 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
AU2014241816B9 (en) 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
WO2016040896A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
WO2018080933A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS229934B2 (en) * 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds

Also Published As

Publication number Publication date
NO954681D0 (no) 1995-11-20
PE31195A1 (es) 1995-10-18
FI955587A0 (fi) 1995-11-20
IL109703A0 (en) 1994-08-26
WO1994027989A1 (en) 1994-12-08
NO954681L (no) 1995-11-20
CZ305195A3 (en) 1996-06-12
AU6928794A (en) 1994-12-20
HUT73790A (en) 1996-09-30
PL311702A1 (en) 1996-03-04
CA2162921A1 (en) 1994-12-08
JPH08510455A (ja) 1996-11-05
TW279866B (enExample) 1996-07-01
ZA943494B (en) 1995-01-23
FI955587A7 (fi) 1995-11-20
EP0699196A1 (en) 1996-03-06
GB9310635D0 (en) 1993-07-07
BG100154A (en) 1996-07-31
SK142495A3 (en) 1996-06-05
CN1126473A (zh) 1996-07-10
HU9503321D0 (en) 1996-01-29

Similar Documents

Publication Publication Date Title
EP0699196A1 (en) Carbazole derivatives with 17,20-lyase-inhibiting activity
EP1373224B1 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
IE904146A1 (en) Indole Derivatives
AU2014300894A1 (en) Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
US6689798B2 (en) Benzofuran derivatives
SU1549485A3 (ru) Способ получени производных 6-метиленандроста-1,4-диен-3,17-диона
CA2214744C (en) 3-(bis-substituted phenylmethylene)oxindole derivatives
CA2553345C (en) Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
US5578630A (en) Heterocyclic compounds which inhibit aromatase
KR19980702319A (ko) 이미다졸 유도체 및 이의 의약 조성물
Branchaud Studies on the development of the tritylsulfenyl group as a nitrogen protecting group and application in a synthesis of. delta.-coniceine
EP0240263B1 (en) Indenopyrimidine derivatives
DK149469B (da) 3,5-disubstitueret 1h-1,2,4-triazolderivat til anvendelse som antireproduktivt middel
HU229135B1 (en) Benzofurane derivatives
KR102406248B1 (ko) Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물
US5726196A (en) Aromatase-inhibiting composition containing azole derivative
JPS6258354B2 (enExample)
HU191597B (en) Process for producing of 2-/2-indalin/-imadazoline preparates and medical preparates consisting of such substances
HUT59107A (en) Process for producing new 4(5)-imidazole derivatives having aromatase inhibiting activity and pharmaceutical compositions comprising same as active ingredient
US4064177A (en) 3-Alkoxy-D-homo-C-nor-13α, 14α-gona-1,3,5,(10),6,8-pentaen-17-one and derivatives thereof
JPS6256471A (ja) 含窒素四環式化合物
US4055649A (en) 4-Alkyl-2,6-di-(secondary or tertiary alkyl)amino-3-formylpyridines pharmaceutical compositions thereof and their use in the treatment of obesity and diabetes
JP2002030063A (ja) スルファメート化合物の製造方法
JPS6172763A (ja) プレニルベンズイミダゾ−ル誘導体および抗潰瘍剤
GB2034710A (en) 1H-1,2,4-triazoles